Results 61 to 70 of about 6,081 (225)

Pathological Disulfide Bond Crosslinking: Molecular Insights into Amyloidogenesis and Diseases Progression

ChemBioChem, Volume 26, Issue 18, September 18, 2025.
This review explores pathological disulfide‐crosslinking as a key driver of amyloidogenic protein misfolding and aggregation. Oxidative and ER stress pathways contributing to disease progression are discussed and emerging therapeutic strategies targeting disulfide‐linked aggregates in neurodegenerative and systemic amyloid diseases are examined ...
Dong Min Kang, Nataliia Lukianenko, Ja‐Hyun Baik, Yun Kyung Kim, Sungsu Lim   +4 more
wiley   +1 more source

Synergistic Effects of Moderate Therapeutic Hypothermia and Levosimendan on Cardiac Function and Survival After Asphyxia‐Induced Cardiac Arrest in Rats

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
Background This study investigated whether levosimendan, an inotropic calcium sensitizer, when combined with moderate therapeutic hypothermia, may exert synergistic benefits on post–cardiac arrest myocardial dysfunction and improve outcomes.
Chih‐Hung Wang, Wei‐Tien Chang, Min‐Shan Tsai, Chien‐Hua Huang, Wen‐Jone Chen   +4 more
doaj   +1 more source

Intermittent inotropic therapy with levosimendan vs. milrinone in advanced heart failure patients

ESC Heart Failure, 2022
Aims Routine, intermittent inotropic therapy (IIT) is still applied in advanced heart failure (HF) patients either as a bridge to definitive treatment or as a mean to improve quality of life (QOL), despite limited evidence to support its' use.
Assi Milwidsky, Shir Frydman, Michal Laufer‐Perl, Ben Sadeh, Orly Sapir, Yoav Granot, Aviram Hochstadt, Liuba Korotetski, Liora Ketchker, Yan Topilsky, Shmuel Banai, Ofer Havakuk   +11 more
doaj   +1 more source

Systematic Exploration of Potential Druggable Genes for Ischemic Stroke Employing Genome‐Wide Mendelian Randomization Analysis

Brain and Behavior, Volume 15, Issue 9, September 2025.
This study identified six potential druggable genes (CALCRL, KCNJ11, NEK3, THSD1, MMP12, and HSD17B12) associated with ischemic stroke risk using a systematic druggable genome‐wide Mendelian randomization analysis. ABSTRACT Background Ischemic stroke (IS) treatment remains a significant challenge.
Peng Zhang, Yulu He, Qing Zhen, Yan Zhang   +3 more
wiley   +1 more source

Prophylactic use of levosimendan in pediatric patients undergoing cardiac surgery: a prospective randomized controlled trial

Critical Care, 2019
Background The administration of levosimendan prophylactically to patients undergoing cardiac surgery remains a controversial practice, and few studies have specifically assessed the value of this approach in pediatric patients.
Anbiao Wang, Chaomei Cui, Yiou Fan, Jie Zi, Jie Zhang, Guanglai Wang, Fang Wang, Jun Wang, Qi Tan   +8 more
doaj   +1 more source

Levosimendan is superior to epinephrine on coronary flow for lipid-base resuscitation of bupivacaine-induced asystole in the isolated rat heart

BMC Anesthesiology, 2018
Background Successful resuscitation from asystole induced by bupivacaine requires the reestablishment of a sufficient coronary flow (CF) quickly. This study was designed to test whether levosimendan was superior to epinephrine in the reestablishment of ...
Hongfei Chen, Fangfang Xia, Zhousheng Jin, Kejian Shi, Yun Xia, Le Liu, Thomas J. Papadimos, Xuzhong Xu, Limei Chen   +8 more
doaj   +1 more source

Efficacy of levosimendan in shock

Critical Care, 2004
Levosimendan is used intravenously for the management of heart failure. At the therapeutic dose, levosimendan acts predominantly as a calcium sensitizer and ATP-sensitive K+-channel (KATP-channel) opener. It binds directly to the calcium-dependent site on troponin C, stabilizing the calcium-induced conformational change and enhances the calcium ...
Stephen Huang, Benjamin Tang, D Stewart, Marek Nalos, Anthony S. McLean   +4 more
openaire   +2 more sources

eComment. Consider trying levosimendan [PDF]

Interactive CardioVascular and Thoracic Surgery, 2013
Levosimendan is a well established drug used nowadays routinely for the treatment of heart failure both in cardiology [1] as well as in cardiac surgery [2] despite the relatively high costs of administration [3] and the few, one must admit, adverse effects [4]. The review article by Angadi et al.
openaire   +3 more sources

Percutaneous mechanical circulatory support for acute right heart failure: A practical approach

ESC Heart Failure, Volume 12, Issue 4, Page 2652-2668, August 2025.
This is an overview of percutaneous mechanical circulatory support options for acute right heart failure, illustrating key clinical scenarios, device types, and principles of tailored device selection based on haemodynamics and underlying pathology. Abstract Acute right heart failure (RHF) represents a critical entity with significant morbidity and ...
Mario Gramegna, Christophe Vandenbriele, Guido Tavazzi, Mir B. Basir, Caroline Bleakley, Mario Iannaccone, Daniel Kretzschmar, Francesco Maisano, Anna Mara Scandroglio, Benedikt Schrage, P. Christian Schultze, Gregory Serrao, Matthew Tomey, Richard Trimlett, Dirk Westermann, Matteo Montorfano, George Dangas, Susanna Price, Alaide Chieffo   +18 more
wiley   +1 more source

The therapeutic effect of levosimendan in patients with prolonged ventilator weaning and cardiac dysfunction

Journal of International Medical Research
Objective To explore the therapeutic effect of levosimendan in patients with prolonged ventilator weaning and cardiac dysfunction. Method Patients with prolonged ventilator weaning and cardiac dysfunction were randomly allocated to receive conventional ...
Fang Xiong, Zongjun Hu, Chao Liu, Kexiang Zhang, Qilong Zhou, Jianguo Chen, Hua Lu, Xi Yue, Jianxin Zhao, Pengfei Pan   +9 more
doaj   +1 more source